Drug Innovation
Enriching Lawyers Is Not the Solution to the Opioid Crisis
Effective health care reforms must reduce the excessive costs imposed by frivolous lawsuits. Studies have shown that medical tort reform could reduce total health care premiums between 1 and 3 percent. As estimated by the American Action Forum, this could mean “roughly $15 billion” in savings from effective (but partial) …
Reforms Should Improve the Efficiency of the Pharmaceutical Market
The refrain that pharmaceuticals are driving the health care affordability problem has been repeated so often that it is becoming an illusory truth – people believe it to be true simply because they have heard it repeated so often. Obviously, repeating the same incorrect statement over and over again does …
ISSUE BRIEF: Nevada Proposal To Regulate Excess Costs Are Price Controls By Another Name
Click here to download a copy of PRI’s Issue Brief Senate Bill 265 would require pharmaceutical firms to reimburse insurers for any “excess costs” associated with drugs for diabetes, which are defined as the excess costs over the highest price in other developed countries. The Fiscal Notes on SB 265 …
Oregon’s Drug Price Bill Is Hard To Swallow
President Donald Trump is not the only politician saying he is going to work to get drug prices down. Oregon lawmakers are already patting themselves on the back for tackling drug prices. Rep. Mitch Greenlick (D-Portland) says the measure, Oregon House Bill 2387, could be a model for national reform. …
ISSUE BRIEF: Oregon Proposal To Regulate Excess Costs Is Price Controls By Another Name
Introduced in February, HB 2387 would require pharmaceutical firms to reimburse insurers for any “excess costs” associated with covered drugs. Excess costs are defined as the difference between the average wholesale price of a drug and either: the typical price in other countries; or, the difference between a health plan’s …
Issue Brief: Proposal To Regulate Excess Costs Is Price Controls By Another Name
Introduced in February, HB 2387 would require pharmaceutical firms to reimburse insurers for any “excess costs” associated with covered drugs. Excess costs are defined as the difference between the average wholesale price of a drug and either: the typical price in other countries; or, the difference between a health plan’s …
The New Senate’s Top Priority: Destroying Drug Innovation?
Minnesota Senator Amy Klobuchar just introduced a federal budget amendment that would legalize the importation of foreign prescription drugs. This particular policy change has long topped Democrats’ health care wish list, but shockingly, they might find support across the aisle this year, as President-elect Trump has spoken glowingly of importation. …
Empowering Frivolous Healthcare Litigation Does Not Help Patients
Of all the problems troubling the U.S. healthcare system, too little litigation is not one of them. And yet, the “Creating and Restoring Equal Access to Equivalent Samples Act of 2016” (CREATES Act), which is currently being rushed through Congress, takes just such an approach. If implemented, the CREATES Act …
Hillary’s Price Controls Would Kill New Drug Innovation
Like your iPhone? Federal officials designed it. Couldn’t live without the Internet? Thank Uncle Sam — he invented it. Sick and need new medicine? Don’t worry — the government is here to help. This fantastical line of thinking — that because the government funded basic, early-stage research, it can claim …
The Senate should reject foreign drug importation
Congress must send a budget to President Obama by next Friday. Senate lawmakers, hoping to avoid a government shutdown, have just started sparring over the details of their reconciliation measure. Sen. John McCain (R-Ariz.) has introduced an amendment to legalize the importation of certain prescription drugs from abroad. On the …
Enriching Lawyers Is Not the Solution to the Opioid Crisis
Effective health care reforms must reduce the excessive costs imposed by frivolous lawsuits. Studies have shown that medical tort reform could reduce total health care premiums between 1 and 3 percent. As estimated by the American Action Forum, this could mean “roughly $15 billion” in savings from effective (but partial) …
Reforms Should Improve the Efficiency of the Pharmaceutical Market
The refrain that pharmaceuticals are driving the health care affordability problem has been repeated so often that it is becoming an illusory truth – people believe it to be true simply because they have heard it repeated so often. Obviously, repeating the same incorrect statement over and over again does …
ISSUE BRIEF: Nevada Proposal To Regulate Excess Costs Are Price Controls By Another Name
Click here to download a copy of PRI’s Issue Brief Senate Bill 265 would require pharmaceutical firms to reimburse insurers for any “excess costs” associated with drugs for diabetes, which are defined as the excess costs over the highest price in other developed countries. The Fiscal Notes on SB 265 …
Oregon’s Drug Price Bill Is Hard To Swallow
President Donald Trump is not the only politician saying he is going to work to get drug prices down. Oregon lawmakers are already patting themselves on the back for tackling drug prices. Rep. Mitch Greenlick (D-Portland) says the measure, Oregon House Bill 2387, could be a model for national reform. …
ISSUE BRIEF: Oregon Proposal To Regulate Excess Costs Is Price Controls By Another Name
Introduced in February, HB 2387 would require pharmaceutical firms to reimburse insurers for any “excess costs” associated with covered drugs. Excess costs are defined as the difference between the average wholesale price of a drug and either: the typical price in other countries; or, the difference between a health plan’s …
Issue Brief: Proposal To Regulate Excess Costs Is Price Controls By Another Name
Introduced in February, HB 2387 would require pharmaceutical firms to reimburse insurers for any “excess costs” associated with covered drugs. Excess costs are defined as the difference between the average wholesale price of a drug and either: the typical price in other countries; or, the difference between a health plan’s …
The New Senate’s Top Priority: Destroying Drug Innovation?
Minnesota Senator Amy Klobuchar just introduced a federal budget amendment that would legalize the importation of foreign prescription drugs. This particular policy change has long topped Democrats’ health care wish list, but shockingly, they might find support across the aisle this year, as President-elect Trump has spoken glowingly of importation. …
Empowering Frivolous Healthcare Litigation Does Not Help Patients
Of all the problems troubling the U.S. healthcare system, too little litigation is not one of them. And yet, the “Creating and Restoring Equal Access to Equivalent Samples Act of 2016” (CREATES Act), which is currently being rushed through Congress, takes just such an approach. If implemented, the CREATES Act …
Hillary’s Price Controls Would Kill New Drug Innovation
Like your iPhone? Federal officials designed it. Couldn’t live without the Internet? Thank Uncle Sam — he invented it. Sick and need new medicine? Don’t worry — the government is here to help. This fantastical line of thinking — that because the government funded basic, early-stage research, it can claim …
The Senate should reject foreign drug importation
Congress must send a budget to President Obama by next Friday. Senate lawmakers, hoping to avoid a government shutdown, have just started sparring over the details of their reconciliation measure. Sen. John McCain (R-Ariz.) has introduced an amendment to legalize the importation of certain prescription drugs from abroad. On the …
